• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

基于社区的肿瘤学实践中与骨髓抑制性化疗相关贫血的护理模式。

Patterns of care in community-based oncology practices for anemia associated with myelosuppressive chemotherapy.

机构信息

University of California Los Angeles, Los Angeles; McKesson Specialty Care Solutions, San Rafael; ICON Clinical Research, Lifecycle Sciences Group, San Francisco; and Amgen, Thousand Oaks, CA.

出版信息

J Oncol Pract. 2009 Sep;5(5):236-43. doi: 10.1200/JOP.091011.

DOI:10.1200/JOP.091011
PMID:20856735
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2790673/
Abstract

Use of erythropoiesis-stimulating agents in the treatment of myelosuppresive chemotherapy-induced anemia has been shown to increase hemoglobin levels and reduce the need for transfusions in patients with cancer.

摘要

促红细胞生成素刺激剂在治疗骨髓抑制性化疗引起的贫血方面的应用已被证明可以提高血红蛋白水平并减少癌症患者的输血需求。

相似文献

1
Patterns of care in community-based oncology practices for anemia associated with myelosuppressive chemotherapy.基于社区的肿瘤学实践中与骨髓抑制性化疗相关贫血的护理模式。
J Oncol Pract. 2009 Sep;5(5):236-43. doi: 10.1200/JOP.091011.
2
Effect of reimbursement changes on erythropoiesis-stimulating agent utilization and transfusions.报销政策变化对红细胞生成刺激剂的使用和输血的影响。
Am J Hematol. 2010 Nov;85(11):838-43. doi: 10.1002/ajh.21837.
3
Benefits of early intervention with erythropoiesis- stimulating proteins in chemotherapy-induced anemia.化疗所致贫血早期使用促红细胞生成蛋白进行干预的益处。
Oncology (Williston Park). 2006 Jul;20(8 Suppl 6):16-20.
4
Changes in the use of erythropoiesis-stimulating agents (ESAs) and red blood cell transfusion in patients with cancer amidst regulatory and reimbursement changes.在监管和报销政策变化的背景下，癌症患者促红细胞生成素刺激剂（ESAs）和红细胞输血使用情况的变化。
Pharmacoepidemiol Drug Saf. 2017 Nov;26(11):1357-1366. doi: 10.1002/pds.4293. Epub 2017 Aug 14.
5
Transfusion practice patterns in patients with anemia receiving myelosuppressive chemotherapy for nonmyeloid cancer: results from a prospective observational study.接受非髓性恶性肿瘤骨髓抑制性化疗的贫血患者的输血实践模式：一项前瞻性观察性研究的结果。
Support Care Cancer. 2018 Jun;26(6):2031-2038. doi: 10.1007/s00520-017-4035-7. Epub 2018 Jan 19.
6
Adherence to guidelines for use of erythropoiesis-stimulating agents in patients with chemotherapy-induced anemia: results of a retrospective study of an electronic medical-records database in the United States, 2002-2006.化疗所致贫血患者促红细胞生成素类药物使用指南的依从性：2002 - 2006年美国电子病历数据库回顾性研究结果
Clin Ther. 2008 Dec;30(12):2423-35. doi: 10.1016/j.clinthera.2008.12.022.
7
Epidemiology of Chemotherapy-Induced Anemia in Patients with Non-Hodgkin Lymphoma.非霍奇金淋巴瘤患者化疗所致贫血的流行病学
Perm J. 2019;23. doi: 10.7812/TPP/18-252. Epub 2019 Jun 27.
8
Erythropoiesis-stimulating agents in gynecological malignancies: A study-level meta-analysis.妇科恶性肿瘤中的促红细胞生成素：一项研究水平的荟萃分析。
Crit Rev Oncol Hematol. 2016 Mar;99:123-8. doi: 10.1016/j.critrevonc.2015.12.013. Epub 2015 Dec 29.
9
Erythropoiesis-stimulating agents (ESAs): do they still have a role in chemotherapy-induced anemia (CIA)?促红细胞生成素刺激剂（ESAs）：它们在化疗引起的贫血（CIA）中仍有作用吗？
Crit Rev Oncol Hematol. 2013 Aug;87(2):132-9. doi: 10.1016/j.critrevonc.2012.12.010. Epub 2013 Jan 26.
10
Real-world utilization of darbepoetin alfa in cancer chemotherapy patients.癌症化疗患者中阿法达贝泊汀的真实世界应用情况。
J Oncol Pharm Pract. 2019 Jan;25(1):16-24. doi: 10.1177/1078155217725571. Epub 2017 Aug 17.

引用本文的文献

1
Commentary: do guidelines influence physician practice behavior? The experience with erythropoiesis-stimulating agents.评论：指南是否会影响医生的执业行为？促红细胞生成素的应用经验
J Oncol Pract. 2009 Sep;5(5):243-4. doi: 10.1200/JOP.091012.

本文引用的文献

1
Utilization of darbepoetin alfa in relation to cancer patients' hemoglobin levels.促红细胞生成素α在癌症患者血红蛋白水平方面的应用。
Curr Med Res Opin. 2008 Mar;24(3):815-9. doi: 10.1185/030079908X280383. Epub 2008 Feb 6.
2
The background and methodology of the Anaemia Cancer Treatment (A.C.T.) study: a global retrospective study of practice patterns and outcomes in the management of anaemia in cancer patients and their congruence with evidence-based guidelines.贫血癌症治疗（A.C.T.）研究的背景与方法：一项关于癌症患者贫血管理实践模式及结果的全球回顾性研究，以及这些模式与循证指南的一致性。
Support Care Cancer. 2008 Feb;16(2):193-200. doi: 10.1007/s00520-007-0311-2. Epub 2007 Sep 14.
3
Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: a systematic review of the literature.促红细胞生成素和达比加群酯对化疗所致贫血患者的临床益处与风险：文献系统评价
Clin Ther. 2006 Jun;28(6):801-31. doi: 10.1016/j.clinthera.2006.06.003.
4
Erythropoietin or darbepoetin for patients with cancer.促红细胞生成素或达比加群用于癌症患者。
Cochrane Database Syst Rev. 2006 Jul 19(3):CD003407. doi: 10.1002/14651858.CD003407.pub4.
5
Cancer-related anemia and recombinant human erythropoietin--an updated overview.癌症相关性贫血与重组人促红细胞生成素——最新综述
Nat Clin Pract Oncol. 2006 Mar;3(3):152-64. doi: 10.1038/ncponc0451.
6
The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients.欧洲癌症贫血调查（ECAS）：一项大型、跨国、前瞻性调查，旨在确定癌症患者贫血的患病率、发病率及治疗情况。
Eur J Cancer. 2004 Oct;40(15):2293-306. doi: 10.1016/j.ejca.2004.06.019.
7
Cancer-related fatigue: evolving concepts in evaluation and treatment.癌症相关疲劳：评估与治疗中的概念演变
Cancer. 2003 Nov 1;98(9):1786-801. doi: 10.1002/cncr.11742.
8
Multidimensional independent predictors of cancer-related fatigue.癌症相关疲劳的多维独立预测因素。
J Pain Symptom Manage. 2003 Jul;26(1):604-14. doi: 10.1016/s0885-3924(03)00218-5.
9
Fatigue in patients with advanced cancer: a review.晚期癌症患者的疲劳：综述
Int J Gynecol Cancer. 2002 Sep-Oct;12(5):424-8. doi: 10.1046/j.1525-1438.2002.t01-1-01147.x.
10
Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology.促红细胞生成素在癌症患者中的应用：美国临床肿瘤学会和美国血液学会基于证据的临床实践指南
J Clin Oncol. 2002 Oct 1;20(19):4083-107. doi: 10.1200/JCO.2002.07.177.